Psilocybin Research

Historical context

Psilocybin research began in the 1950s and 1960s with promising early results in addiction, depression, and end-of-life anxiety. Criminalization under the Controlled Substances Act in 1970 halted almost all clinical work for three decades. Research restarted in the 2000s when researchers at Johns Hopkins University and Imperial College London obtained FDA authorization to study psilocybin in human subjects again.

Since 2000, the field has accumulated a substantial body of peer-reviewed evidence across multiple conditions. As of 2026, multiple phase 2 and phase 3 clinical trials are underway at institutions across North America and Europe.

What is psilocybin?

Psilocybin is a naturally occurring indole alkaloid found in approximately 200 species of fungi worldwide. In the body it converts to psilocin, which acts as a partial agonist at serotonin 2A receptors (5-HT2A), particularly in the prefrontal cortex. Onset is typically 20–40 minutes after oral ingestion, with a peak at 90–120 minutes and a total duration of 4–6 hours.

[CONTENT GAP: toxicology and safety profile, verify LD50, addiction potential, and organ toxicity figures with medical reviewer]

FDA Breakthrough Therapy designation

FDA Breakthrough Therapy designation is an expedited review pathway for drugs showing "substantial improvement" over existing treatments in early clinical evidence. It is not approval, but it signals the FDA considers the evidence compelling enough to warrant faster review.

Psilocybin received FDA Breakthrough Therapy designation for treatment-resistant depression (2018) and for PTSD-related applications (2021). [dates pending medical review confirmation] Active trials include COMP360 (Compass Pathways) for treatment-resistant depression across approximately 100 sites globally, and multiple Johns Hopkins studies in nicotine addiction, alcohol use disorder, and major depressive disorder.

Key findings

• ✓Johnson et al. (Johns Hopkins, 2014): 80% of nicotine-addicted participants abstinent at 6-month follow-up after psilocybin-assisted therapy, substantially above standard cessation rates.
• ✓Carhart-Harris et al. (Imperial College, 2016): marked reductions in depression severity in 12 treatment-resistant patients; effects sustained at 3-month follow-up.
• ✓Davis et al. (Johns Hopkins, 2021): large, rapid, and durable antidepressant effects in major depressive disorder in a randomized controlled trial.
• ✓Griffiths et al. (Johns Hopkins, 2016): substantial and sustained decreases in depression and anxiety in cancer patients facing life-threatening diagnosis.

What this means for Ceremonia participants

Ceremonia operates within Colorado's regulated psilocybin services framework, which draws on this research base to define safe dosing protocols, screening criteria, and facilitation standards. Participants benefit from decades of clinical evidence translated into practice.

The research consistently shows that set, setting, and integration support are as important as the compound itself. That is why Ceremonia invests heavily in preparation, facilitation quality, and post-ceremony integration, not just ceremony logistics.